arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

PALISADE BIO, INC.

PALI
$1.16 ▼ -0.10 (-8.30%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Neutral
auto_awesome

Analytical Summary

PALISADE BIO, INC. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $245.2M
Dividend Yield —
Revenue Growth None
Op. Margin —
ROIC -7.6% ↘
FCF / Share $-0.04 ↘
Trailing P/E —
Price / Book 1.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$500.00K
— —
Net Income Profit after all expenses
$-10.57M
↓ -279.8% —
FCF / Share Free cash flow per share
$-0.04
↓ -93.9% —
Long-Term Debt Long-term obligations
$568.00K
↓ -50.2% —

Health Breakdown

Returns
32
Financial Health ↓
3
Cash Quality ↑
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 18 years · 68 quarters